ClinicalTrials.gg
CompletedNCT04684420Updated Dec 29, 2023Results posted

GXR RM (Glucophage® Extended Release Reduced Mass) 500 Milligram (mg) Korea Bioequivalence (BE) Study

A Phase 1 interventional study of Glucophage® XR RM Test and Glucophage® XR Reference in Healthy, sponsored by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-29.

Sponsored by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (part of Merck KGaA, Darmstadt, Germany) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
81
Allocation
Randomized
Ages
19 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 113 studies testing metformin in Diabetes Mellitus — 7 open to participants now, 7 under way, 1 of them phase 3. Metformin · Diabetes Mellitus.

Enrollment
68th of 112
81 · median 108
Started
2020
with 4 others
Phase 1
15 of 113
2 open now
Registered
103rd of 113
by date

Among the 113 studies testing metformin in Diabetes Mellitus, this one is the 68th largest by enrollment of the 112 interventional ones that give a count, is one of 5 that started in 2020, is one of 15 in phase 1, and was the 103rd registered.

Diabetes Mellitus

8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

7 of the 113 studies testing metformin in Diabetes Mellitus are open now, in 6 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About metformin

Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.

This study: 19 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies testing metformin in Diabetes Mellitus, or all of them as a file.
02

Study summary

The purpose of this study was to assess bioequivalence (BE) of newly developed Glucophage® XR (GXR) reduced mass (RM) tablet (metformin hydrochloride 500 milligrams (mg) test tablet) and marketed Glucophage ® XR tablet (metformin hydrochloride 500 mg reference tablet) following single oral dose administration under fasted and fed conditions by comparing pharmacokinetics, safety and tolerability between test and reference in healthy participants.

03

Conditions studied

  • Healthy

Browse trials for

Keywords

  • Diabetes Mellitus
  • Glucophage Extended Release
  • Bioequivalence Study
04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All values for hematology and biochemistry tests of blood and urinalysis (especially Estimated [eGFR] greater than [>] 80 milliliters per minute per 1.73 square meter [80 ml/min/1.73 m\^2] and normal Creatinine) within the normal range or showing no deviation as judged by the Investigator
  • Are not having congenital or chronic diseases, nor pathological symptoms based on the screening
  • Have no history of gastrointestinal resection that may affect drug absorption
  • Have no history of psychiatric disorder within 5 years prior to screening
  • Vital signs (body temperature [tympanic], blood pressure [BP], and pulse rate in sitting position) within the normal range or showing no clinically relevant deviation as judged by the Investigator
  • recording (12-lead) without signs of clinically relevant pathology in particular (Bazett) less than or equal to [\<=] 450 millisecond (ms)
  • Non-smoker (that is [i.e.] zero cigarettes, pipes, cigars or others) at least three months before study entry
  • Negative screen for surface antigen (HBsAg) and Hepatitis B Virus antibody (anti-HBc), Virus antibody (anti-HCV) and antibodies (anti-HIV 1 and 2) and Rapid Plasma Reagin Antibody (RPR Ab)
  • Have a body weight within the range 55 to 95 kilograms (kg) and a (BMI) within the range 18.5 to 29.9 kilograms per square meter (kg/m\^2) (inclusive)
  • Other protocol defined inclusion criteria could apply

Exclusion criteria

Exclusion Criteria:

  • Participants determined ineligible to participate in this study at the discretion of the Principal Investigator (or delegated investigators)
  • to venous puncture
  • Known hypersensitivity to ingredients of Study Interventions or Biguanides, or having other hypersensitivities
  • Type I diabetes mellitus, lactic acidosis, acute or chronic metabolic acidosis including diabetic ketoacidosis, with or without coma; diabetic pre-coma, pre-diabetes
  • Participants with renal impairment ( \< 80 ml/min/1.73m\^2) - calculations according to Modification of Diet in Renal Disease (MDRD) formula). Participants presenting with acute conditions with the potential to alter renal function such as dehydration, severe infection, cardiovascular collapse (shock), acute myocardial infraction, and septicemia
  • Participants with acute and unstable heart failure
  • Participants with severe infection or severe traumatic general disorder
  • Participants who are scheduled to undergo surgical procedures
  • Participants with malnutrition, inanition, pituitary dysfunction or adrenal function failure
  • Participants with hepatic dysfunction, acute or chronic disease which may cause tissue hypoxia such as respiratory failure, acute myocardial infarction, shock and gastrointestinal (GI) disorder such as excessive alcohol intake, hydration, diarrhea, vomiting etc.
  • Participants undergoing intravascular administration of iodinated contrast materials in radio diagnostic examinations (for example, intravenous urogram, intravenous cholangiography, angiography, and computed tomography (CT) scans with intravascular contrast materials etc.)
  • Participants who took drugs that significantly induce (e.g., barbiturate) or inhibit drug metabolism enzymes, and those drugs that may alter metformin pharmacokinetic (pK), most importantly organic cation transporter 1/2 [OCT1/2] inhibitors and inducers, within 30 days prior to screening
  • Use of a concomitant drug. However, any medications that are considered necessary for participant's welfare and will not interfere with the trial medication may be given at the discretion of the investigator
  • Use of any medication that may affect the outcome of the study within 10 days prior to screening and during study conduct
  • Participation in another bioequivalence or other clinical studies where the last administration of previous study medication was within 6 months, before the first drug administration in this study
  • Other protocol defined exclusion criteria could apply
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
81 participants (actual)

Study arms

  • Experimental
    First Reference GXR (Fasting), Then Test GXR RM (Fasting)

    Participants received a single oral dose of 500 milligram (mg) of reference GXR (Glucophage® Extended Release) tablet on Day 1 in treatment period 1 followed by single oral dose of 500 mg test GXR RM (Reduced Mass) tablet on Day 8 in treatment period 2 under fasting conditions. There was a washout period of 7 days between two treatment period.

    Drug: Glucophage® XR RM Test · Drug: Glucophage® XR Reference

  • Experimental
    First Test GXR RM (Fasting), Then Reference GXR (Fasting)

    Participants received a single oral dose of 500 milligrams (mg) of test GXR RM tablet on Day 1 in treatment period 1 followed by single oral dose of 500 mg of reference GXR tablet on Day 8 in treatment period 2 under fasting conditions. There was a washout period of 7 days between two treatment period.

    Drug: Glucophage® XR RM Test · Drug: Glucophage® XR Reference

  • Experimental
    First Reference GXR (Fed), Then Test GXR RM (Fed)

    Participants received a single oral dose of 500 milligrams (mg) of reference GXR tablet on Day 1 in treatment period 1 followed by single oral dose of 500 mg of test GXR RM tablet on Day 8 in treatment period 2 under fed conditions. There was a washout period of 7 days between two treatment period.

    Drug: Glucophage® XR RM Test · Drug: Glucophage® XR Reference

  • Experimental
    First Test GXR RM (Fed), Then Reference GXR (Fed)

    Participants received a single oral dose of 500 milligrams (mg) of test GXR RM tablet on Day 1 in treatment period 1 followed by single oral dose of 500 mg of reference GXR tablet on Day 8 in treatment period 2 under fed conditions. There was a washout period of 7 days between two treatment period.

    Drug: Glucophage® XR RM Test · Drug: Glucophage® XR Reference

Interventions

  • Participants received a single oral dose of 500 mg of test Glucophage® XR RM tablet under fasting or fed conditions.

    Also known as: Metformin hydrochloride

  • Participants received a single oral dose of 500 mg of reference Glucophage® XR tablet under fasting or fed conditions.

    Also known as: Metformin hydrochloride

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast) of Metformin

    Area under the plasma concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule.

    Time frame: Part 1 (fasted): Pre-dose and 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24 and 32 hours post dose. Part 2 (fed): Pre-dose 1, 2, 3, 4, 5, 5.5, 6, 6.5, 7, 8, 9, 10, 12, 24 and 32 hours post dose

  2. Maximum Observed Plasma Concentration (Cmax) of Metformin

    Cmax was obtained directly from the concentration versus time curve.

    Time frame: Part 1 (fasted): Pre-dose and 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24 and 32 hours post dose. Part 2 (fed): Pre-dose 1, 2, 3, 4, 5, 5.5, 6, 6.5, 7, 8, 9, 10, 12, 24 and 32 hours post dose

Secondary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs

    An Adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. An AE was considered as 'treatment emergent' if it occurred after the first drug administration of each period or if it was present prior to drug administration but exacerbated after the drug administration. TEAEs included both Serious TEAEs and non-serious TEAEs.

    Time frame: From Day 1 up to 3 weeks

  2. Number of Participants Taking Concomitant Medications

    Concomitant medications included medications administered from the first administration of study interventions to the end of observation.

    Time frame: From Day 1 up to 3 weeks

  3. Number of Participants With Clinically Significant Change From Baseline in Laboratory Values

    The laboratory measurements included hematology, blood chemistry, urinalysis and Blood Sugar Test (BST). Number of participants with clinically significant changes from baseline in laboratory values were reported. Clinically Significance was decided by investigator.

    Time frame: From Day1 (baseline) up to 3 weeks

  4. Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiogram (ECG) Findings

    The 12-lead ECG recordings were obtained after 5 minutes of rest in a semi-supine position. ECG recordings included rhythm, ventricular rate, PR interval, QRS duration, QT and QTc intervals. Number of participants with clinically significant changes from baseline in 12-lead ECG findings were reported. Clinically significance was decided by investigator.

    Time frame: From Day 1 (baseline) up to 3 weeks

  5. Number of Participants With Clinically Significant Change From Baseline in Vital Signs

    Vital sign assessment included blood pressure, pulse rate, body temperature and respiration rate. Number of participants with clinically significant changes from baseline in vital signs were reported. Clinically significance was decided by investigator.

    Time frame: From Day 1 (baseline) up to 3 weeks

  6. Number of Participants With Clinically Significant Change From Baseline in Physical Examination Findings

    Physical examination included assessments of the skin, lungs, cardiovascular system, abdomen (liver and spleen), and the symptoms reported by the participant. Number of participants with clinically significant changes from baseline in vital signs were reported. Clinically significance was decided by investigator.

    Time frame: From Day 1 (baseline) up to 3 weeks

  7. Area Under Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Metformin

    AUC0-inf was calculated by combining AUC0-t and AUC extra. AUC extra represents an extrapolated value obtained by Clast/ lambda z, where Clast is the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the Lower Limit of quantification (LLQ) and lambda z is the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.

    Time frame: Part 1 (fasted): Pre-dose and 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24 and 32 hours post dose. Part 2 (fed): Pre-dose 1, 2, 3, 4, 5, 5.5, 6, 6.5, 7, 8, 9, 10, 12, 24 and 32 hours post dose

  8. Ratio of Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC0-tlast) to Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Metformin

    The ratio of AUClast to AUCinf were reported.

    Time frame: Part 1 (fasted): Pre-dose and 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24 and 32 hours post dose. Part 2 (fed): Pre-dose 1, 2, 3, 4, 5, 5.5, 6, 6.5, 7, 8, 9, 10, 12, 24 and 32 hours post dose

  9. Apparent Terminal Half-Life (t1/2) of Metformin

    Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by lambda z.

    Time frame: Part 1 (fasted): Pre-dose and 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24 and 32 hours post dose. Part 2 (fed): Pre-dose 1, 2, 3, 4, 5, 5.5, 6, 6.5, 7, 8, 9, 10, 12, 24 and 32 hours post dose

  10. Time to Reach Maximum Observed Plasma Concentration (Tmax) of Metformin

    Time to reach the maximum plasma concentration (Tmax) was obtained directly from the concentration versus time curve.

    Time frame: Part 1 (fasted): Pre-dose and 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24 and 32 hours post dose. Part 2 (fed): Pre-dose 1, 2, 3, 4, 5, 5.5, 6, 6.5, 7, 8, 9, 10, 12, 24 and 32 hours post dose

07

Results

Posted Dec 29, 2023

Participant flow

A total of 56 participants were screened for the study in Part 1 (Fasted state) out of which 48 were randomized. For Part 2 (Fed state), a total of 49 participants were screened out of which 33 were randomized.

Treatment Period 1 (Day 1)
Participant flow — Treatment Period 1 (Day 1)
MilestoneFirst Reference GXR (Fasting), Then Test GXR RM Tablet (Fasting)First Test GXR RM (Fasting), Then Reference GXR (Fasting)First Reference GXR (Fed), Then Test GXR RM (Fed)First Test GXR RM (Fed), Then Reference GXR (Fed)
Started24241716
Completed24231515
Not completed0121
Withdrew: Withdrawal by subject0021
Withdrew: Adverse event0100
Period 2(Day 8 up to 3 Months)
Participant flow — Period 2(Day 8 up to 3 Months)
MilestoneFirst Reference GXR (Fasting), Then Test GXR RM Tablet (Fasting)First Test GXR RM (Fasting), Then Reference GXR (Fasting)First Reference GXR (Fed), Then Test GXR RM (Fed)First Test GXR RM (Fed), Then Reference GXR (Fed)
Started24231515
Completed24231515
Not completed0000

Outcome measures

PrimaryArea Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast) of Metformin

Area under the plasma concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule.

Time frame:
Part 1 (fasted): Pre-dose and 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24 and 32 hours post dose. Part 2 (fed): Pre-dose 1, 2, 3, 4, 5, 5.5, 6, 6.5, 7, 8, 9, 10, 12, 24 and 32 hours post dose
Reported as:
Geometric mean · hour*nanogram per milliter (hr*ng/ml)
Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast) of Metformin
hour*nanogram per milliter (hr*ng/ml)Reference GXR (Fasting)Test GXR RM (Fasting)Reference GXR (Fed)Test GXR RM (Fed)
Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast) of Metformin3627.171 ± 31.94076.521 ± 30.46981.833 ± 18.16564.938 ± 26.4
PrimaryMaximum Observed Plasma Concentration (Cmax) of Metformin

Cmax was obtained directly from the concentration versus time curve.

Time frame:
Part 1 (fasted): Pre-dose and 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24 and 32 hours post dose. Part 2 (fed): Pre-dose 1, 2, 3, 4, 5, 5.5, 6, 6.5, 7, 8, 9, 10, 12, 24 and 32 hours post dose
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax) of Metformin
nanogram per milliliter (ng/mL)Reference GXR (Fasting)Test GXR RM (Fasting)Reference GXR (Fed)Test GXR RM (Fed)
Maximum Observed Plasma Concentration (Cmax) of Metformin605.347 ± 31.7677.651 ± 31.2590.956 ± 18.9671.864 ± 16.7
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs

An Adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. An AE was considered as 'treatment emergent' if it occurred after the first drug administration of each period or if it was present prior to drug administration but exacerbated after the drug administration. TEAEs included both Serious TEAEs and non-serious TEAEs.

Time frame:
From Day 1 up to 3 weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs
ParticipantsReference GXR (Fasting)Test GXR RM (Fasting)Reference GXR (Fed)Test GXR RM (Fed)
TEAEs7732
Serious TEAEs0000
SecondaryNumber of Participants Taking Concomitant Medications

Concomitant medications included medications administered from the first administration of study interventions to the end of observation.

Time frame:
From Day 1 up to 3 weeks
Reported as:
Count of participants · Participants
Number of Participants Taking Concomitant Medications
ParticipantsReference GXR (Fasting)Test GXR RM (Fasting)Reference GXR (Fed)Test GXR RM (Fed)
Number of Participants Taking Concomitant Medications0000
SecondaryNumber of Participants With Clinically Significant Change From Baseline in Laboratory Values

The laboratory measurements included hematology, blood chemistry, urinalysis and Blood Sugar Test (BST). Number of participants with clinically significant changes from baseline in laboratory values were reported. Clinically Significance was decided by investigator.

Time frame:
From Day1 (baseline) up to 3 weeks
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Change From Baseline in Laboratory Values
ParticipantsReference GXR (Fasting)Test GXR RM (Fasting)Reference GXR (Fed)Test GXR RM (Fed)
Hematology0000
Biochemistry0000
Urinalysis0000
Blood Sugar Test (BST)0000
SecondaryNumber of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiogram (ECG) Findings

The 12-lead ECG recordings were obtained after 5 minutes of rest in a semi-supine position. ECG recordings included rhythm, ventricular rate, PR interval, QRS duration, QT and QTc intervals. Number of participants with clinically significant changes from baseline in 12-lead ECG findings were reported. Clinically significance was decided by investigator.

Time frame:
From Day 1 (baseline) up to 3 weeks
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiogram (ECG) Findings
ParticipantsReference GXR (Fasting)Test GXR RM (Fasting)Reference GXR (Fed)Test GXR RM (Fed)
Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiogram (ECG) Findings0000
SecondaryNumber of Participants With Clinically Significant Change From Baseline in Vital Signs

Vital sign assessment included blood pressure, pulse rate, body temperature and respiration rate. Number of participants with clinically significant changes from baseline in vital signs were reported. Clinically significance was decided by investigator.

Time frame:
From Day 1 (baseline) up to 3 weeks
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Change From Baseline in Vital Signs
ParticipantsReference GXR (Fasting)Test GXR RM (Fasting)Reference GXR (Fed)Test GXR RM (Fed)
Number of Participants With Clinically Significant Change From Baseline in Vital Signs0000
SecondaryNumber of Participants With Clinically Significant Change From Baseline in Physical Examination Findings

Physical examination included assessments of the skin, lungs, cardiovascular system, abdomen (liver and spleen), and the symptoms reported by the participant. Number of participants with clinically significant changes from baseline in vital signs were reported. Clinically significance was decided by investigator.

Time frame:
From Day 1 (baseline) up to 3 weeks
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Change From Baseline in Physical Examination Findings
ParticipantsReference GXR (Fasting)Test GXR RM (Fasting)Reference GXR (Fed)Test GXR RM (Fed)
Number of Participants With Clinically Significant Change From Baseline in Physical Examination Findings0000
SecondaryArea Under Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Metformin

AUC0-inf was calculated by combining AUC0-t and AUC extra. AUC extra represents an extrapolated value obtained by Clast/ lambda z, where Clast is the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the Lower Limit of quantification (LLQ) and lambda z is the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.

Time frame:
Part 1 (fasted): Pre-dose and 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24 and 32 hours post dose. Part 2 (fed): Pre-dose 1, 2, 3, 4, 5, 5.5, 6, 6.5, 7, 8, 9, 10, 12, 24 and 32 hours post dose
Reported as:
Geometric mean · hr*ng/ml
Area Under Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Metformin
hr*ng/mlReference GXR (Fasting)Test GXR RM (Fasting)Reference GXR (Fed)Test GXR RM (Fed)
Area Under Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Metformin3911.152 ± 30.84370.051 ± 28.67297.899 ± 16.46833.321 ± 23.6
SecondaryRatio of Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC0-tlast) to Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Metformin

The ratio of AUClast to AUCinf were reported.

Time frame:
Part 1 (fasted): Pre-dose and 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24 and 32 hours post dose. Part 2 (fed): Pre-dose 1, 2, 3, 4, 5, 5.5, 6, 6.5, 7, 8, 9, 10, 12, 24 and 32 hours post dose
Reported as:
Geometric mean · Ratio
Ratio of Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC0-tlast) to Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Metformin
RatioReference GXR (Fasting)Test GXR RM (Fasting)Reference GXR (Fed)Test GXR RM (Fed)
Ratio of Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC0-tlast) to Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Metformin0.927 ± 4.70.933 ± 3.20.953 ± 9.90.961 ± 3.5
SecondaryApparent Terminal Half-Life (t1/2) of Metformin

Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by lambda z.

Time frame:
Part 1 (fasted): Pre-dose and 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24 and 32 hours post dose. Part 2 (fed): Pre-dose 1, 2, 3, 4, 5, 5.5, 6, 6.5, 7, 8, 9, 10, 12, 24 and 32 hours post dose
Reported as:
Geometric mean · hours
Apparent Terminal Half-Life (t1/2) of Metformin
hoursReference GXR (Fasting)Test GXR RM (Fasting)Reference GXR (Fed)Test GXR RM (Fed)
Apparent Terminal Half-Life (t1/2) of Metformin3.520 ± 60.13.769 ± 47.14.122 ± 19.53.386 ± 21.1
SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax) of Metformin

Time to reach the maximum plasma concentration (Tmax) was obtained directly from the concentration versus time curve.

Time frame:
Part 1 (fasted): Pre-dose and 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24 and 32 hours post dose. Part 2 (fed): Pre-dose 1, 2, 3, 4, 5, 5.5, 6, 6.5, 7, 8, 9, 10, 12, 24 and 32 hours post dose
Reported as:
Median · hours
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Metformin
hoursReference GXR (Fasting)Test GXR RM (Fasting)Reference GXR (Fed)Test GXR RM (Fed)
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Metformin3.500 (2.000 to 5.000)3.500 (1.000 to 5.000)5.500 (4.000 to 10.000)5.010 (5.000 to 8.000)

Adverse events

Collected over From informed consent (Day-28 to Day-2) up to 3 weeks, a maximum of 49 days.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Reference GXR (Fasting)0/47 (0%)0/47 (0%)7/47 (14.9%)
Test GXR RM (Fasting)0/48 (0%)0/48 (0%)7/48 (14.6%)
Reference GXR (Fed)0/32 (0%)0/32 (0%)3/32 (9.4%)
Test GXR RM (Fed)0/31 (0%)0/31 (0%)2/31 (6.5%)
Most frequent other events
Showing 10 of 13
Most frequent other events
EventReference GXR (Fasting)Test GXR RM (Fasting)Reference GXR (Fed)Test GXR RM (Fed)
Electrocardiogram PR prolongationInvestigations3/472/480/321/31
Electrocardiogram QT prolongedInvestigations0/470/482/320/31
Human chorionic gonadotropin increasedInvestigations2/470/480/320/31
White blood cells urine positiveInvestigations2/472/481/321/31
PresyncopeNervous system disorders0/472/480/320/31
White blood cell count increasedInvestigations0/470/480/321/31
Blood creatine phosphokinase increasedInvestigations1/471/480/320/31
Alanine aminotransferase increasedInvestigations1/470/480/320/31
Aspartate aminotransferase increasedInvestigations1/470/480/320/31
Blood creatinine increasedInvestigations1/471/480/320/31

Baseline characteristics

Demographic population included all those participants who participated in the bioequivalence study (that is all participants who were randomized)

Age, Categorical
Age, Categorical(Participants)First Reference GXR (Fasting), Then Test GXR RM (Fasting)First Test GXR RM (Fasting), Then Reference GXR (Fasting)First Reference GXR (Fed), Then Test GXR RM (Fed)First Test GXR RM (Fed), Then Reference GXR (Fed)Total
<=18 years00000
Between 18 and 65 years2424171681
>=65 years00000
Sex: Female, Male
Sex: Female, Male(Participants)First Reference GXR (Fasting), Then Test GXR RM (Fasting)First Test GXR RM (Fasting), Then Reference GXR (Fasting)First Reference GXR (Fed), Then Test GXR RM (Fed)First Test GXR RM (Fed), Then Reference GXR (Fed)Total
Female775322
Male1717121359
Race (NIH/OMB)
Race (NIH/OMB)(Participants)First Reference GXR (Fasting), Then Test GXR RM (Fasting)First Test GXR RM (Fasting), Then Reference GXR (Fasting)First Reference GXR (Fed), Then Test GXR RM (Fed)First Test GXR RM (Fed), Then Reference GXR (Fed)Total
American Indian or Alaska Native00000
Asian2424171681
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White00000
More than one race00000
Unknown or Not Reported00000
08

Study locations

1 site
  • Clinical Trials Center, Chungnam National University Hospital
    Daejeon, 35015, Korea, Republic of
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — We are committed to enhancing public health through responsible sharing of clinical trial data. Following approval of a new product or a new indication for an approved product in both the US and the European Union, the study sponsor and/or its affiliated companies will share study protocols, anonymized patient data and study level data, and redacted clinical study reports with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website https://bit.ly/IPD21

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in Mar 2022, 14 months.

Results were first posted in Dec 2023, 1 year 9 months after primary completion.

Of 171 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 10. This study's 14 months is above that.

Counting every sponsor, half of 247 studies reached it within 7 months; a quarter within 3 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2020
First posted
Dec 24, 2020
StartActual
Dec 22, 2020
Primary completionActual
Mar 11, 2022
CompletionActual
Mar 11, 2022
Results first posted
Dec 29, 2023
Last update
Dec 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04684420
Responsible party
Sponsor
First posted
Dec 24, 2020
Start date
Dec 22, 2020
Primary completion
Mar 11, 2022
Completion
Mar 11, 2022
Results posted
Dec 29, 2023
Last update
Dec 29, 2023

Study contacts

Medical Responsible
study director · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metformin

Start the discussion